Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 3/20 | 0.46 |
| ▸ | UBE2N | P61088 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 2/20 | 0.44 |
| ▸ | HRH2 | P25021 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5649529 | 0.85 | NPC1 (0.50) | NPC1RAB9AMCHR1ESR1UBE2N | |
| SCHEMBL5650685 | 0.84 | NPC1 (0.48) | NPC1RAB9AMCHR1ESR1UBE2N | |
| SCHEMBL5650538 | 0.81 | PPARG (0.49) | NPC1RAB9AMCHR1ESR1UBE2N | |
| SCHEMBL5648384 | 0.80 | PDE6D (0.41) | NPC1RAB9AHRH3KMT2A | |
| SCHEMBL5648611 | 0.79 | NPC1 (0.54) | NPC1RAB9AMCHR1ESR1LTA4H | |
| SCHEMBL5650413 | 0.78 | ALDH1A1 (0.42) | KMT2AADORA2AADORA1 | |
| SCHEMBL3627057 | 0.70 | NPC1 (0.51) | NPC1RAB9AMCHR1ESR1LTA4H | |
| SCHEMBL5652540 | 0.70 | HPGD (0.52) | KMT2A | |
| SCHEMBL11898739 | 0.70 | NPC1 (0.97) | NPC1RAB9AESR1LTA4HHRH2 | |
| SCHEMBL5652071 | 0.68 | HTT (0.51) | RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7176215-B2 | Bicyclic oxopyridine and oxopyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2007-02-13 | — | — | US | disclosed |
| US-20040254200-A1 | Bicyclic oxopyridine and oxopyrimidine derivatives | UCB PHARMA S.A. (BE) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254200-A1 | Bicyclic oxopyridine and oxopyrimidine derivatives | MAPK1, ALK, NAT1 | NPC1 1606/4885RAB9A 3641/4885MCHR1 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.